CME/CE

The role of antibody-drug conjugate (ADC) therapy has been well established in metastatic breast cancer. Recent phase 3 data have provided evidence for expanded indications for early breast cancer and triple-negative breast cancer (TNBC), leading to updates in current treatment guidelines. In this case-based activity, Drs. Tiffany Traina and Sara Hurvitz explore the supporting data for use of ADCs in the neoadjuvant, post-neoadjuvant, and metastatic TBNC settings.

This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell engagers, and antibody-drug conjugates. Faculty discuss emerging clinical evidence for investigational approaches across both extensive-stage and limited-stage disease settings. Emphasis is placed on how disease stage, prior treatment exposure, mechanism of action, and evolving trial data can inform treatment selection, clinical trial referral, and future integration of antigen-directed therapies into SCLC care.

This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell engagers, and antibody-drug conjugates. Faculty discuss emerging clinical evidence for investigational approaches across both extensive-stage and limited-stage disease settings. Emphasis is placed on how disease stage, prior treatment exposure, mechanism of action, and evolving trial data can inform treatment selection, clinical trial referral, and future integration of antigen-directed therapies into SCLC care.

This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell engagers, and antibody-drug conjugates. Faculty discuss emerging clinical evidence for investigational approaches across both extensive-stage and limited-stage disease settings. Emphasis is placed on how disease stage, prior treatment exposure, mechanism of action, and evolving trial data can inform treatment selection, clinical trial referral, and future integration of antigen-directed therapies into SCLC care.

This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell engagers, and antibody-drug conjugates. Faculty discuss emerging clinical evidence for investigational approaches across both extensive-stage and limited-stage disease settings. Emphasis is placed on how disease stage, prior treatment exposure, mechanism of action, and evolving trial data can inform treatment selection, clinical trial referral, and future integration of antigen-directed therapies into SCLC care.

This program is a replay of the live symposium held at ENDO 2026. This program reviews challenges in diagnosis and management of acromegaly, with an emphasis on earlier recognition and informed clinical decision-making. Faculty discuss heterogeneity of disease presentation and key triggers that should prompt biochemical testing. Guideline-informed strategies for treatment selection, sequencing, and optimization are reviewed for patients with partial disease control, persistent symptoms, or comorbidities. The activity also examines disease burden, therapeutic inertia, and emerging treatment options, including oral therapies, with a focus on individualized care for patients with acromegaly in endocrine practice.

This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence from key clinical trials, including KEYNOTE-689 and NIVOPOSTOP. The discussions highlight treatment selection, multidisciplinary coordination among surgical, medical, and radiation oncology teams, and practical considerations such as PD-L1 testing, radiologic assessment, and management of immune-related adverse events. Through expert commentary and a patient case, the program explores strategies for incorporating perioperative immunotherapy into clinical practice and identifying appropriate candidates for this treatment approach.

This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence from key clinical trials, including KEYNOTE-689 and NIVOPOSTOP. The discussions highlight treatment selection, multidisciplinary coordination among surgical, medical, and radiation oncology teams, and practical considerations such as PD-L1 testing, radiologic assessment, and management of immune-related adverse events. Through expert commentary and a patient case, the program explores strategies for incorporating perioperative immunotherapy into clinical practice and identifying appropriate candidates for this treatment approach.

This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence from key clinical trials, including KEYNOTE-689 and NIVOPOSTOP. The discussions highlight treatment selection, multidisciplinary coordination among surgical, medical, and radiation oncology teams, and practical considerations such as PD-L1 testing, radiologic assessment, and management of immune-related adverse events. Through expert commentary and a patient case, the program explores strategies for incorporating perioperative immunotherapy into clinical practice and identifying appropriate candidates for this treatment approach.

This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence from key clinical trials, including KEYNOTE-689 and NIVOPOSTOP. The discussions highlight treatment selection, multidisciplinary coordination among surgical, medical, and radiation oncology teams, and practical considerations such as PD-L1 testing, radiologic assessment, and management of immune-related adverse events. Through expert commentary and a patient case, the program explores strategies for incorporating perioperative immunotherapy into clinical practice and identifying appropriate candidates for this treatment approach.